Siemens, Gamma Medica sign worldwide marketing agreement for X-SPECT

Siemens Medical Solutions and Gamma Medica Inc. announced this week at the SNM meeting in Philadelphia that they have expanded the scope of their 2003 marketing agreement.

Under the terms of the new agreement, Siemens will market and distribute Gamma Medica's X-SPECT molecular imaging product worldwide. Since July 2003, Siemens has held exclusive U.S. marketing rights for the system.

X-SPECT is Gamma Medica's second-generation MicroSPECT pre-clinical imaging system. The dual-modality system combines functional nuclear imaging technique, single photon emission computed tomography (SPECT), with anatomical imaging provided by CT. The system images on a scale 1,000 times smaller than clinical systems and is equipped with dedicated features for the in-vivo imaging of small animals in pre-clinical settings.

Since signing the agreement with Siemens last year, Gamma Medica says that X-SPECT sales have increased dramatically and will continue to with the expansion of the pair's contract.

X-SPECT is installed at a variety of universities, medical centers and biotech and pharmaceutical companies. Most recently, Gamma Medica says it completed installation of the pre-clinical imaging system at Mayo Clinic in Rochester, Minn.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup